Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Pierre Chue

Pierre Chue

University of Alberta, Canada

Title: Perspectives on the administration of intramuscular (IM) long acting antipsychotic injections (LAIs) in mental health clients

Biography

Biography: Pierre Chue

Abstract

Objectives

  1. Review the second generation atypical antipsychotics (SGA) LAIs.
  2. Understand the differential pharmacokinetics (pK) of deltoid vs. gluteal injections.
  3. Discuss Canadian nursing best practice and patient acceptance.

Introduction

The (SGAs) risperidone, paliperidone, aripiprazole are available in Canada as long acting injections (LAIs) given at intervals of two weeks to three months. Although initially developed as formulations for gluteal intramuscular (IM) injection, all are now approved for deltoid injection in volumes of up to 2.7 mL (for paliperidone 3-monthly). 

Methodology

The international literature was reviewed in the context and discussed in the context of Canadian nursing best practice.

Results

Recent data suggest deltoid vs. gluteal IM injections are associated with shorter TMAX and greater CMAX, thus potentially offering a different exposure and clinical response and tolerability. For mental health clients deltoid injections are associated with less stigma, greater convenience and greater practicality in multiple clinical scenarios. Current Canadian nursing practice recommends gluteal as the preferred route for irritating, viscous and larger volumes, with a maximum of 2 mL in a well-developed deltoid muscle.

Conclusion

Advantages and disadvantages of deltoid vs. gluteal IM injections of LAIs should be considered in the context of Canadian nursing best practice, pK and real world practicality.